Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from boosted protease inhibitor plus Truvada to Stribild in virologically suppressed adults with HIV-1
2011-004483-30Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Switch to EVG/COBI/FTC/TDF with Continue PI/r + FTC/TDF (2 arms). Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48. Started Nov 2011; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir disoproxil fumarateprotease inhibitor + ritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-004483-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004483-30.